Future directions and targeted therapies in bladder cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hoc.2014.10.008PMID 25836940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma.

  2014cited by this paper
• Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

  2014cited by this paper
• A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

  2014cited by this paper
• 808OINHIBITION OF PD-L1 BY MPDL3280A LEADS TO CLINICAL ACTIVITY IN PTS WITH METASTATIC UROTHELIAL BLADDER CANCER (UBC).

  2014cited by this paper
• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

  2014cited by this paper
• The preclinical activity of lenalidomide in indolent urothelial carcinoma.

  2014cited by this paper
• Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

  2014cited by this paper
• Prospective randomized double‐blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO‐AB 31/05)

  2014cited by this paper
• A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

  2014cited by this paper
• Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

  2014cited by this paper
• Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

  2014cited by this paper
• Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.

  2014cited by this paper
• A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy.

  2014cited by this paper
• Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC).

  2014cited by this paper
• Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC).

  2014cited by this paper
• Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).

  2014cited by this paper
• Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.

  2014cited by this paper
• Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder.

  2014cited by this paper
• Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

  2014cited by this paper
• Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

  2014cited by this paper
• Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

  2013cited by this paper
• Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo.

  2013cited by this paper
• Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy

  2013cited by this paper
• Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.

  2013cited by this paper
• The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo

  2013cited by this paper
• Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

  2013cited by this paper
• Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

  2013cited by this paper
• Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

  2013cited by this paper
• A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

  2013cited by this paper
• A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.

  2013cited by this paper
• Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

  2013cited by this paper
• Phase II study of everolimus in metastatic urothelial cancer

  2013cited by this paper
• Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

  2013cited by this paper
• A new approach to second-line therapy for urothelial cancer?

  2013cited by this paper
• Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

  2013cited by this paper
• Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy

  2013cited by this paper
• Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.

  2013cited by this paper
• A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Multicenter Randomized Phase 2 Trial of Gemcitabine – Platinum with or without Trastuzumab (T) in Advanced / Metastatic Urothelial Carcinoma (A/MUC) with HER2 Overexpression

  2012cited by this paper
• High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.

  2012cited by this paper
• Three differentiation states risk-stratify bladder cancer into distinct subtypes

  2012cited by this paper
• Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

  2012cited by this paper
• Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

  2012cited by this paper
• Genome Sequencing Identifies a Basis for Everolimus Sensitivity

  2012cited by this paper
• Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

  2012cited by this paper
• Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

  2012cited by this paper
• A Molecular Taxonomy for Urothelial Carcinoma

  2012cited by this paper
• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

  2012cited by this paper
• Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

  2012cited by this paper
• Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

  2012cited by this paper
• FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

  2012cited by this paper
• Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.

  2011cited by this paper
• Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

  2011cited by this paper
• A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

  2011cited by this paper
• Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder.

  2011cited by this paper
• Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder.

  2011cited by this paper
• Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.

  2011cited by this paper
• A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1

  2011cited by this paper
• Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

  2011cited by this paper
• Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

  2011cited by this paper
• Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

  2011cited by this paper
• Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

  2010cited by this paper
• Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

  2010cited by this paper
• Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

  2010cited by this paper
• Phase II study of sunitinib in patients with metastatic urothelial cancer.

  2010cited by this paper
• Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

  2010cited by this paper
• Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)--Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

  2010cited by this paper
• Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

  2010cited by this paper
• Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

  2010cited by this paper
• A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

  2009cited by this paper
• A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

  2009cited by this paper
• Phase 2 trial of sorafenib in patients with advanced urothelial cancer

  2009cited by this paper
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

  2009cited by this paper
• Effect of Vascular Endothelial Growth Factor and Its Receptor Inhibitor on Proliferation and Invasion in Bladder Cancer

  2009cited by this paper
• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

  2009cited by this paper
• Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

  2009cited by this paper
• Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells

  2007cited by this paper
• Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

  2007cited by this paper
• Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

  2007cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

  2006cited by this paper
• Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

  2005cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.

  2001cited by this paper
• Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

  1999cited by this paper
• Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer?

  1999cited by this paper
• Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer?

  1999cited by this paper
• Prognostic value of amplification of c-erb-B2 in bladder carcinoma.

  1995cited by this paper
• Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.

  1995cited by this paper
• Journal of Translational Medicine the Histone Deacetylase Inhibitor Belinostat (pxd101) Suppresses Bladder Cancer Cell Growth in Vitro and in Vivo

  year unknowncited by this paper

• Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways

  2022cites this paper
• Epidemiology and unmet needs of bladder cancer in Italy: a critical review.

  2020cites this paper
• Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression

  2019cites this paper
• Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway

  2018cites this paper
• Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway

  2018cites this paper
• Precision Molecular Pathology of Bladder Cancer

  2018influential citation
• Unmet informational and supportive care needs of patients with muscle invasive bladder cancer: A systematic review of the evidence.

  2018cites this paper
• Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder

  2018cites this paper
• Challenges in the management of urothelial cancer : novel treatment, evaluation of biomarkers, and imaging techniques

  2018cites this paper
• Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from the Cancer Genome Atlas (TCGA) Project

  2018cites this paper
• Contemporary update on neoadjuvant therapy for bladder cancer

  2017cites this paper
• Emerging role of Hippo signalling pathway in bladder cancer

  2017cites this paper
• Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

  2017cites this paper
• A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma

  2017cites this paper
• An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer

  2016cites this paper
• Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

  2016cites this paper
• Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

  2016cites this paper
• Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer

  2016cites this paper
• Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer.

  2016cites this paper
• Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.

  2016cites this paper
• Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

  2016cites this paper
• Radiolabeling and cell incorporation studies of gemcitabine HCl microspheres on bladder cancer and papilloma cell line

  2016cites this paper
• Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise

  2015cites this paper
• Muscle-invasive urothelial bladder cancer: an update on systemic therapy

  2015cites this paper